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MaBACKGROUND Angina is common in hypertrophic cardiomyopathy (HCM) and is associated with abnormal myocardial
perfusion. Wave intensity analysis improves the understanding of the mechanics of myocardial ischemia.
OBJECTIVES Wave intensity analysis was used to describe the mechanisms underlying perfusion abnormalities in
patients with HCM.
METHODS Simultaneous pressure and ﬂow were measured in the proximal left anterior descending artery in 33 patients
with HCM and 20 control patients at rest and during hyperemia, allowing calculation of wave intensity. Patients also
underwent quantitative ﬁrst-pass perfusion cardiac magnetic resonance to measure myocardial perfusion reserve.
RESULTS Patients with HCM had a lower coronary ﬂow reserve than control subjects (1.9  0.8 vs. 2.7  0.9;
p ¼ 0.01). Coronary hemodynamics in HCM were characterized by a very large backward compression wave during
systole (38  11% vs. 21  6%; p < 0.001) and a proportionately smaller backward expansion wave (27%  8% vs.
33  6%; p ¼ 0.006) compared with control subjects. Patients with severe left ventricular outﬂow tract obstruction had
a bisferiens pressure waveform resulting in an additional proximally originating deceleration wave during systole. The
proportion of waves acting to accelerate coronary ﬂow increased with hyperemia, and the magnitude of change was
proportional to the myocardial perfusion reserve (rho ¼ 0.53; p < 0.01).
CONCLUSIONS Coronary ﬂow in patients with HCM is deranged. Distally, compressive deformation of intramyocardial
blood vessels during systole results in an abnormally large backward compression wave, whereas proximally, severe left
ventricular outﬂow tract obstruction is associated with an additional deceleration wave. Perfusion abnormalities in HCM
are not simply a consequence of supply/demand mismatch or remodeling of the intramyocardial blood vessels; they
represent a dynamic interaction with the mechanics of myocardial ischemia that may be amenable to treatment.
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ABBR EV I A T I ON S
AND ACRONYMS
BCW = backward compression
wave
BCWtot = backward
compression wave
BEW = backward expansion
wave
CFR = coronary ﬂow reserve
FCW = forward compression
wave
FCWa = additional forward
compression wave
FEW = forward expansion
wave
FEWa = additional forward
expansion wave
HCM = hypertrophic
cardiomyopathy
LGE = late gadolinium
enhancement
LVOT = left ventricular
outﬂow tract
MBF = myocardial blood ﬂow
MPR = myocardial perfusion
reserve
WIA = wave intensity anal
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1652H ypertrophic cardiomyopathy (HCM)afﬂicts 1 in 500 of the general popu-lation (1). Chest pain affects up to
one-half of patients and is believed to result
from impaired myocardial perfusion (2).
Although it is difﬁcult to treat (3), severe
perfusion abnormalities are independently
predictive of death (4) and development of
heart failure (5).SEE PAGE 1661Several potential mechanisms have been
proposed to explain these perfusion abnor-
malities, including increased oxygen
requirements due to hypertrophy, impaired
ventricular relaxation, anatomic abnormal-
ities of intramyocardial arterioles, and left
ventricular outﬂow tract (LVOT) obstruction
(3,6–8). However, the relative contribution of
each factor, and the impact of LVOT
obstruction compared with myocardial hy-
pertrophy alone, remains unclear.
Wave intensity analysis (WIA) describes
the waves that cause acceleration or decel-
eration of coronary blood (9), and it has
allowed elucidation of the dominant mech-anisms underlying coronary ﬂow in structurally
normal hearts (10) and aortic stenosis (11). Acceler-
ation of coronary ﬂow results from either compres-
sion waves originating from the aortic (proximal)
end or expansion waves originating from the
microcirculatory (distal) end. Separated wave
intensity allows separation of the proximal and
distal effects, whereas net wave intensity describes
the net result of opposing waves during the
cardiac cycle.
In the healthy heart, coronary ﬂow is largely
governed by 2 waves: the forward compression wave
(FCW), which is generated by ventricular contraction
and accelerates blood into the coronaries, and the
backward expansion wave (BEW), which results from
decompression of the microcirculation as the
ventricle relaxes (Figure 1). The FEW decelerates
coronary ﬂow and occurs as ventricular contraction
slows. Distally, the early and late backward
compression waves (BCWs) occur during systole
as the intramyocardial vessels are compressed (10).
In HCM, there are increased competing forces both
proximally and distally. Proximally, there are changes
in left ventricular (LV) contraction and relaxation and
possible effects of LVOT obstruction; distally, there
are changes due to compressed intramyocardial blood
vessels and dysfunction of the microcirculation.
Coronary ﬂow abnormalities are common in HCM,
ysiswith ﬂow reversal during systole and higher ﬂow
velocities during diastole (12–14).
The goal of the present study was to elucidate the
mechanism of myocardial ischemia and angina in
HCM through the combination of coronary WIA and
cardiac magnetic resonance (CMR) perfusion.
PATIENTS AND METHODS
Consecutive patients with HCM and an indication for
coronary angiography were invited to participate.
Control subjects had a structurally normal heart,
atypical chest pain, an indication for coronary cath-
eterization, and angiographically unobstructed coro-
nary arteries. All participants provided written
informed consent, and the study was approved by an
independent ethics committee.
HCM was deﬁned according to American Heart As-
sociation criteria (15). LVOT obstruction was deﬁned at
the time of cardiac catheterization as a resting gradient
of $30 mm Hg. Exclusion criteria were as follows: 1)
coronary artery disease (deﬁned as>50% narrowing of
epicardial coronary arteries >2 mm); 2) hypertension
not controlled by medical therapy (>140/80 mm Hg at
rest on 2 successive readings); and 3) valvular heart
disease (excluding mitral regurgitation due to systolic
anterior motion of the mitral valve).
Subjects were instructed to abstain from smoking
and consumption of caffeine-containing substances
and nitrate medications for 24 h before examination.
After pressure equalization with the pressure
sensor at the tip of the guiding catheter, the Doppler
velocity and pressure wire (ComboWire, Volcano
Corporation, San Diego, California) was advanced in
the proximal left anterior descending coronary artery
with optimization of the Doppler signal. Simulta-
neous recordings of pressure, ﬂow velocity, and
electrocardiogram were obtained at a sampling rate of
200 Hz at rest and peak hyperemia after an intrave-
nous infusion of adenosine (140 mg/kg/min) for 3 min.
Data were similarly obtained in the proximal
ascending thoracic aorta. LV pressure was recorded at
rest and during hyperemia.
The duration of systole and diastole and time
between onset of diastole (deﬁned by using the
dicrotic notch) (14) to peak coronary ﬂow were
calculated for each patient. The instantaneous coro-
nary volume ﬂow rate was calculated from the
product of the instantaneous ﬂow velocity and the
coronary cross-sectional area measured by using
quantitative coronary angiography (16). The mean
volume coronary ﬂow rate was averaged over the
whole cardiac cycle. Coronary ﬂow reserve (CFR) was
calculated as the mean coronary volume ﬂow rate
FIGURE 1 Separated Wave Intensity
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In the wave intensity analysis (WIA) pattern of patients at rest (top), proximally originating waves are displayed above the axis and distally originating waves
below the axis. Using a different scale, the ensemble averages (bottom panel) show the trajectory of pressure (solid line) and ﬂow velocity (dashed line).
In control subjects, the dominant wave is the backward expansion wave (BEW), but in patients with hypertrophic cardiomyopathy (HCM), the backward
compression wave (BCW) is dominant. Severe left ventricular outﬂow tract (LVOT) obstruction produces additional forward waves. BP ¼ blood pressure;
BCWtot ¼ backward compression wave total; FCW ¼ forward compression wave; FCWa ¼ additional forward compression wave; FCW2 ¼ forward
compression wave 2; FEW ¼ forward expansion wave; FEWa ¼ additional forward expansion wave.
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1653throughout the cardiac cycle at maximal hyperemia
divided by the mean coronary volume ﬂow rate
at rest. Coronary resistance was deﬁned as pressure
divided by ﬂow. Mean coronary resistance was
deﬁned as the mean of the instantaneous resistance
over the relevant period (systole, diastole, or the
entire cardiac period).
WAVE INTENSITY ANALYSIS. Data were analyzed by
using a customized automated MATLAB program
(MathWorks, Natick, Massachusetts) (10). Four to
5 beats of pressure and ﬂow velocity data were
ensemble-averaged, and a Savitzky-Golay ﬁlter (poly-
nomial order 3, frame size 17) was used to calculate the
time derivative of the data (17). The derivatives of
pressure and ﬂow at each time point were used to
calculate the net wave intensity. Waves were catego-
rized in terms of direction (forward [waves of proximal
origin] or backward [waves of distal origin]) and
associated pressure change (compression [a rise in
pressure] or expansion [a fall in pressure]). The sum-
of-squares method was used to determine the wave
speed for calculation of the separated wave intensity(9). Because this method has been shown to be less
accurate under conditions of low coronary resistance
(18), only the net wave intensity was used to compare
rest and hyperemia.
Separated wave intensity allows separation of the
proximal and distal effects, whereas net wave in-
tensity describes the net result of opposing waves
during the cardiac cycle (Online Figure 1). For both
separated wave intensity and net WIA, the cumula-
tive wave intensity was deﬁned as the integral of
wave intensity over a given peak. For comparison
between patients, each wave was also presented as a
proportion of the total cumulative wave intensity
(either separated or net), the percentage of separated
cumulative wave intensity, and the percentage of
separated net wave intensity, respectively (10). The
proportion of total wave intensity comprising accel-
erating waves (forward compression and BEWs) was
also calculated.
CMR DATA ACQUISITION AND ANALYSIS. CMR data
were collected on a 3-T MAGNETOM Skyra scanner
(Siemens Corporation, Malvern, Pennsylvania).
TABLE 1 Patient Characteristics
Control Group
(n ¼ 20)
HCM Group
(n ¼ 33) p Value
Age, yrs 59  15 54  14 0.89
Male 12 (60) 24 (73) 0.34
Wall thickness, mm 10  2 21  4 <0.01
LVOT obstruction 0 (0) 16 (48) <0.01
In NYHA functional
class I/II/III
13/7/0 4/18/11 <0.01
NYHA functional class 1.6  0.5 2.2  0.6 0.03
History of ventricular
tachycardia
0 (0) 3 (9) 0.17
Implantable
cardioverter-deﬁbrillator
0 (0) 2 (6) 0.26
Chest pain 16 (80) 24 (73) 0.55
Shortness of breath 4 (20) 26 (88) <0.01
Syncope 0 (0) 9 (27) 0.01
LVEDVi, ml/m2 130  42 71  21 0.01
LVESVi, ml/m2 41  24 18  9 <0.01
LVEF, % 70  8 73  14 0.07
LVMi, g/m2 63  15 115  41 <0.01
RVEF, % 58  5 65  14 <0.01
LGE, % of total left
ventricular mass
0  0 22.3  14.1 <0.01
Rest MBF, ml/kg/min 1.0  0.3 1.1  0.3 0.56
Hyperemic MBF, ml/kg/min 1.8  0.5 1.5  0.5 0.04
MPR 1.9  0.5 1.4  0.3 <0.01
Resting heart rate, beats/min 68  22 64  11 0.54
Resting systolic
blood pressure, mm Hg
130  16 116  19 0.04
Resting diastolic
blood pressure, mm Hg
70  10 65  15 0.26
LAD diameter, mm 3.1  0.9 3.8  0.6 0.03
LVEDP rest, mm Hg 14.2  2.6 24.4  8.3 <0.01
LVEDP hyperemia, mm Hg 13.6  3.1 27.7  7.1 <0.01
Comorbidities
Hypertension 12 (60) 7 (21) <0.04
Diabetes 2 (10) 1 (3) 0.29
Hypercholesterolemia 12 (60) 4 (12) <0.01
Current smoker 4 (20) 4 (12) 0.44
Medications
Beta-blockers 4 (20) 26 (79) <0.01
ACE inhibitors 8 (40) 3 (9) <0.07
Calcium-channel blockers 0 (0) 6 (18) 0.04
Values are mean  SD, n (%), or n.
ACE ¼ angiotensin-converting enzyme; HCM ¼ hypertrophic cardiomyopathy;
LAD ¼ left anterior descending artery; LGE ¼ late gadolinium enhancement;
LVEDVi ¼ left ventricular end-diastolic volume index; LVEDP ¼ left ventricular
end-diastolic pressure; LVEF ¼ left ventricular ejection fraction; LVESVi ¼ left
ventricular end-systolic volume index; LVMi ¼ left ventricular mass indexed to
body surface area; LVOT ¼ left ventricular outﬂow tract; MBF ¼ myocardial blood
ﬂow; MPR ¼ myocardial perfusion reserve; NYHA ¼ New York Heart Association;
RVEF ¼ right ventricular ejection fraction.
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1654A balanced steady-state free precession sequence was
used to obtain breath-hold cine images in 3 long-axis
planes, followed by a contiguous short-axis stack
through the ventricle. Myocardial ﬁrst-pass perfusion
imaging was performed by using a rate 3, parallel-
accelerated balanced steady-state free precessionsequence (19). Three short-axis images and an image
of the arterial input function were acquired every
cardiac cycle for 70 cycles. Initial proton density–
weighted images were used for subsequent surface
coil intensity correction.
CMR ﬁrst-pass perfusion was recorded at
hyperemia and rest. Adenosine was infused at
140 mg/kg/min by using the same protocol as in the
invasive study. At peak hyperemia, a 0.05–mmol/kg
bolus of gadolinium contrast (Gadovist, Bayer Scher-
ing Pharma AG, Berlin, Germany) was rapidly injected
followed by a 25-ml saline ﬂush. After acquisition of
ﬁrst-pass perfusion, adenosine was stopped, and a
top-up 0.05-mmol/kg bolus of gadolinium was
administered. Late gadolinium enhancement (LGE)
imaging was performed by using an inversion
recovery–prepared, segmented turbo fast low-angle
shot sequence 10 min after gadolinium injection.
The inversion recovery time was optimized to null
normal myocardium. After 20 min, rest perfusion was
similarly performed.
Ventricular volumes, function, and mass were
assessed by using semi-automated CMRtools soft-
ware (Cardiovascular Imaging Solutions, London,
United Kingdom). Myocardial blood ﬂow (MBF) was
calculated by using customized software (Exelis
Visual Information Solutions, Boulder, Colorado) to
correct surface coil intensity bias and motion
artifacts. MBF was quantiﬁed by using model-
constrained deconvolution (20). LGE was quantiﬁed
by using the full-width, half-maximum method, and
ﬁndings are reported as a percentage of total LV mass
using commercially available software (CMR42, Circle
Cardiovascular Imaging, Calgary, Alberta, Canada).
STATISTICAL ANALYSIS. Statistical analysis was
performed by using Stata version 12 (StataCorp LP,
College Station, Texas). Normally distributed data are
presented as mean  SD. Comparisons between
groups were performed by using the Student t test for
2 samples and analysis of variance for 3 variables;
correlation was determined by using the Pearson
correlation coefﬁcient. Nonnormally distributed data
are presented as median and interquartile range and
compared by using the Mann-Whitney U test or
Spearman’s rank test as appropriate. A p value <0.05
was considered signiﬁcant.
RESULTS
Baseline characteristics are shown in Table 1. Of the 33
patients with HCM, 16 had resting LVOT obstruction
(mean gradient 60  36 mm Hg). Two patients with
HCM had minor coronary irregularities, and the
remainder had angiographically normal coronary
TABLE 2 Coronary Flow and Cardiac Cycle Timing
Rest Hyperemia
Control Group HCM Group p Value Control Group HCM Group p Value
Mean coronary ﬂow velocity, m/s 0.19  0.07 0.27  0.11 0.001 0.49  0.18 0.48  0.18 0.78
Cycle length, ms 948  267 937  227 0.68 873  148 864  145 0.60
Duration of diastole, ms 527  157 482  82 0.21 304  115 240  120 0.02
Time between onset of diastole and
peak coronary velocity, ms
109  32 145  72 0.007 114  42 163  76 0.009
Coronary resistance,
mm Hg/ml/min
3.7  1.3 1.9  1.4 <0.001 1.3  0.7 1.1  1.4 0.46
Values are mean  SD.
HCM ¼ hypertrophic cardiomyopathy.
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1655arteries. All control subjects had angiographically
normal coronary arteries. CFR was lower in patients
with HCM compared with control subjects (1.9  0.8
vs. 2.7  0.9; p ¼ 0.01) due to a higher resting mean
coronary ﬂow velocity; there was no signiﬁcant dif-
ference in mean coronary ﬂow velocity during
hyperemia. Differences in cardiac cycle timings be-
tween patients with HCM and control subjects are
shown in Table 2. Flow reversal during systole was
seen in 10 (63%) of 16 patients with HCM with LVOT
obstruction and 3 (18%) of 17 without LVOT obstruc-
tion. No control subjects had ﬂow reversal.
Fourteen (88%) patients with LVOT obstruction
demonstrated a bisferiens pressure waveform in the
proximal left anterior descending coronary artery,
also observed in the proximal aorta. This ﬁnding was
not seen in control subjects or in patients HCM
without resting LVOT obstruction.
Patients with HCM had a continuous backward
compression wave (BCWtot) during early systole
rather than the separate early and late backward
compression waves seen in control subjects. In 14 of
16 patients with LVOT obstruction, there was an
additional forward expansion wave (FEWa) during
ventricular systole, and 9 of 16 patients had an
additional forward compression wave (FCWa) after
the FEWa (Figure 1). These waves coincided with the
transient drop and then rise in proximal left anterior
descending coronary artery pressure seen in the bis-
feriens pressure waveform, coupled with a decrease
in coronary ﬂow velocity (Figure 2).
In HCM, a larger proportion of the total separated
cumulative wave intensity comprised the BCWtot and a
smaller proportion by the BEW compared with control
subjects (Table 3). There was no signiﬁcant difference
in any of the waves between the LVOT obstruction
HCM group and the no-LVOT obstruction HCM group,
with the exception of the additional FCWa and FEWa,
which were present only in the LVOT group. There wasa signiﬁcant correlation between the LVOT gradient
and the FEWa and FCWa (rho ¼ 0.82 [p < 0.001] and
0.40 [p ¼ 0.011], respectively) but no correlation with
the other waves.
IMPACT OF HYPEREMIA. During hyperemia, coro-
nary ﬂow velocity increased and coronary resistance
decreased in all patients. Patients with HCM had a
lower resting mean coronary resistance than control
subjects (Figure 3). Comparing patients with HCM
versus control subjects, resting MBF was similar, but
hyperemic MBF and myocardial perfusion reserve
(MPR) were lower (Table 1).
At rest, there was a higher BCWtot and lower FEW
in patients with HCM compared with control subjects.
The FCW was signiﬁcantly lower, but there was no
signiﬁcant difference in the BEW. During hyperemia,
there was a signiﬁcant increase in the size of all waves
in both groups. The FCW was smaller and the BCWtot
was larger in patients with HCM compared with
control subjects (Table 4; absolute values, Online
Table 1). There was no difference in the BEW. The
ratio of accelerating/decelerating waves at rest was
3.3  1.4 in the control group and 1.9  2.0 in the HCM
group (p < 0.01). During hyperemia, the ratio was
2.2  1.3 in the control group and 1.3  1.1 in the
HCM group (p < 0.01).
MPR correlated with the percent increase in the
proportion of accelerating waves (rho ¼ 0.53; p < 0.01)
(Figure 4). There was no signiﬁcant correlation
between the percent BCWtot at rest and the MBF at rest
(r ¼ –0.25; p ¼ 0.14), but a signiﬁcant correlation was
noted between the proportion of accelerating waves at
rest and MBF at rest (r ¼ 0.35; p ¼ 0.02). There was no
relationship between MPR and wall thickness (r ¼ 0.3;
p ¼ 0.12), LV mass (r ¼ –0.17; p ¼ 0.39), or percent LGE
(–0.012; p ¼ 0.95). There was no relationship between
percent LGE andwave intensitymeasures either at rest
or hyperemia.
FIGURE 2 Origin of Additional Waves Resulting From LVOT Obstruction
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Obstruction of the LVOT due to systolic anterior motion of the mitral valve (top panel,
M mode through mitral valve) results in a transient reduction in outﬂow (middle panel,
continuous wave Doppler) and a decelerating wave (FEWa), which is transmitted into the
coronary arteries. (Bottom panel) This action causes deceleration of coronary ﬂow and a
reduction in coronary pressure. The panels were aligned by the electrocardiogram R wave
with a minimal time delay to account for distance between measurement sites. Abbrevi-
ations as in Figure 1.
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Microvascular ischemia in HCM is associated with
chest pain, clinical deterioration, diastolic dysfunc-
tion, and adverse prognosis (3–5,8). A pressing andunmet need in HCM is a better understanding of
the mechanisms driving myocardial ischemia (15).
Multiple factors contribute, including the following:
increased wall thickness results in both a
supply/demand mismatch and increased compres-
sion of the microcirculation during systole; LVOT
obstruction results in high intracavity pressures
during ventricular systole; and the microcirculatory
vessels themselves have been shown to be
abnormal on histologic analysis (21). Most pharma-
cotherapies in HCM have nonspeciﬁc actions, and
there is consequently still a high burden of
morbidity (22).
This study is the ﬁrst to use wave intensity to
provide detailed analysis of factors affecting coronary
ﬂow in HCM and to measure the impact on myocar-
dial perfusion. Importantly, we assessed the interplay
of upstream and downstream determinants of
microvascular ischemia and described the dominant
mechanisms.
MECHANISMS OF IMPAIRED MYOCARDIAL PERFUSION.
Perfusion abnormalities in HCM have often been
assumed to result simply from supply/demand
mismatch; however, we recorded no correlation be-
tween wall thickness or LV mass and MPR. Rather, we
showed that perfusion abnormalities result from dy-
namic changes in myocardial mechanics throughout
the cardiac cycle.
Three mechanisms were highlighted that result in
impaired myocardial perfusion in HCM and which
might result in symptoms of chest pain and shortness
of breath (Central Illustration). All of these mecha-
nisms might occur separately or simultaneously in a
patient. First, extravascular compressive deforma-
tion of the intramyocardial precapillary arteries and
arterioles during ventricular systole produces a large
BCW. This decelerating wave accounts for the retro-
grade coronary ﬂow in systole seen in some
individuals with HCM. Second, impaired ventricular
relaxation results in a proportionately smaller BEW.
Finally, in some patients with HCM, transient
LVOT obstruction decreases the proximal driving
pressure, resulting in an additional forward deceler-
ation wave that is transmitted into the proximal
coronary artery and diminishes coronary forward
ﬂow. Coronary ﬂow in HCM is therefore deranged,
with opposing forces acting throughout the cardiac
cycle. Myocardial perfusion is determined by the
relative proportion of accelerating and decelerating
waves.
Compression and deformation of the pre-capillary
arteries and arterioles during ventricular systole
result in a very large BCW, sufﬁcient to stop or even
reverse ﬂow in the proximal coronary arteries. Blood
TABLE 3 Separated Cumulative Wave Intensity
Separated Cumulative Wave
Intensity (W m–2s–1  106)
Proportion of Separated Cumulative
Wave Intensity (%)
Control Group HCM Group p Value Control Group HCM Group p Value
FCW 6.6  4.1 7.3  5.1 0.61 26.8  7.4 22.4  10.9 0.09
FEW 2.8  2.5 1.4  1.2 0.005 9.9  4.6 4.2  2.6 <0.001
FEWa 0  0 2.1  2.6 <0.001 0  0 4.1  4.9 0.02
FCWa 0  0 1.3  1.9 0.002 0  0 1.5  4.1 0.08
FCW2 2.2  1.8 1.3  1.4 0.03 9.5  4.1 2.3  4.6 <0.001
BCWtot 4.9  3.0 13  8.3 <0.001 21.0  6.2 38.2  11.1 <0.001
BEW 8.3  5.1 9.8  6.5 0.4 32.8  6.2 27.2  7.9 0.006
Values are mean  SD.
BCWtot ¼ backward compression wave total; BEW ¼ backward expansion wave; FCW ¼ forward compression
wave; FCW2 ¼ forward compression wave 2; FCWa ¼ additional forward compression wave; FEW ¼ forward
expansion wave; FEWa ¼ additional forward expansion wave; HCM ¼ hypertrophic cardiomyopathy.
FIGURE 3 Resting Coronary Resistance
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Mean coronary resistance was deﬁned as the mean of the instantaneous resistance over the
entire cardiac period. Resistance was lowest in HCM patients with LVOT obstruction and
highest in control subjects. Abbreviations as in Figure 1.
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1657is squeezed back from the intramyocardial vessels
toward the epicardial coronary arteries, and the
increased compression of the arterioles results in
higher impedances within these vessels.
The lower coronary resistance in HCM during
diastole resulted in higher diastolic coronary ﬂow in
the present study patients. This ﬁnding suggests that
despite the adverse remodeling and reduction in
vessel density observed in HCM (21), vasodilation of
the microcirculation is sufﬁcient to normalize the
myocardial perfusion at rest, at the expense of the
CFR.
In control subjects, the ratio of the net cumulative
wave intensity of the FCW to the BCW was approxi-
mately 2:1 (Table 4), resulting in acceleration of cor-
onary ﬂow during early systole. In HCM, this ratio was
reversed to approximately 1:2, causing deceleration
during early systole. The situation was worsened
during hyperemia, in which the ratio was reduced to
1:4, and reversal of blood ﬂow direction was even
greater.
As the ventricle relaxes, compression of the intra-
myocardial vessels is relieved, generating a BEW that
accelerates coronary ﬂow. In the present HCM cohort,
the BCW during ventricular contraction was greater
than the BEWduring ventricular relaxation, whichwas
the opposite of the pattern seen in control subjects.
Patients with HCM typically have diastolic impairment
(23,24) with a prolonged time to reach peak diastolic
ﬂow compared with control subjects and a raised end-
diastolic pressure. Diastolic dysfunction results from
increased wall thickness and myocardial ﬁbrosis,
leading to delayed relaxation and increased passive
stiffness. It is therefore unsurprising that BEW did
not correlate with the percentage of replacement
ﬁbrosis alone.
IMPACT OF LVOT OBSTRUCTION. Patients with
severe LVOT obstruction exhibited a bisferiens pres-
sure wave in the proximal aorta. This outcome has
previously been shown to result from transient
obstruction of the LVOT (25). The bisferiens pressure
wave is transmitted into the carotid artery, where it
can be palpated clinically (26). We have shown that it
is also transmitted into the proximal coronary artery
in the form of FEWa, followed by FCWa when the
obstruction is relieved.
Although a larger BCW or smaller BEW might be
expected in patients with LVOT obstruction
compared with those without, clinically HCM is
extremely heterogeneous. Both waves will be
affected by the degree of diastolic dysfunction,
myocardial ﬁbrosis, and ventricular contractility;
it is therefore not surprising that division of thepresent patient cohort according to presence of
LVOT obstruction yielded no signiﬁcant differences
between the 2 subgroups.
The relative timing of systole and diastole further
disadvantages patients with LVOT obstruction, which
prolongs the duration of LV ejection at the expense of
the diastolic phase (27). Despite the favorable reduc-
tion in microcirculatory resistance during diastole,
the duration of diastolic coronary ﬂow is reduced.
TABLE 4 Proportion of Net Cumulative Wave Intensity (%) at Rest and Hyperemia
Rest Hyperemia
Control Group HCM Group p Value Control Group HCM Group p Value
FCW, % 30.1  14.9 15.7  17.5 0.004 24.7  15.1 11.7  13.1 0.002
FEW, % 8.8  7.3 2.5  3.1 <0.001 6.9  6.9 2.7  3.4 0.006
FCWa, % 0  0 7.4  7.2* <0.001 0  0 9.4  9.4* <0.001
FEWa, % 0  0 3.9  2.7* <0.001 0  0 2.2  1.3* <0.001
FCW2, % 6.0  6.7 3.2  8.1 0.21 2.1  3.9 1.0  2.1 0.17
BCWtot, % 16.6  9.5 38.3  19.2 <0.001 27.9  12.6 43.2  14.2 <0.001
BEW, % 38.6  13.5 37.2  12.3 0.70 38.4  10.3 38.7  11.2 0.90
Values are mean  SD. *Means were calculated only for the patients with the additional wave (FCWa, n ¼ 14;
FEWa, n ¼ 9).
Abbreviations as in Tables 1 and 3.
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1658The situation is exacerbated at higher heart rates,
with an even shorter diastolic time despite increased
basal metabolic requirements.
WAVE INTENSITY DURING HYPEREMIA. Resting
coronary ﬂow was higher in patients with HCM
compared with control subjects, although myocardial
perfusion was similar. Patients with HCM had both a
reduced CFR and MPR. The ratio of accelerating/
decelerating waves was lower in patients with HCM
compared with control subjects, both at rest and
during hyperemia. Myocardial perfusion is complexy Wave Intensity and Myocardial Perfusion in HCM
100 200 300 400 500
oportionate Increase in % Accelerating Waves
rho = 0.53
p<0.01
sion reserve (MPR) was measured using cardiac magnetic resonance
ed with the changes in wave intensity between rest and hyperemia.
nt correlation between the MPR and the proportionate increase in
rating waves during hyperemia. HCM ¼ hypertrophic cardiomyopathy.and mediated by waves generated both proximally
and distally throughout the cardiac cycle. Adenosine
produces a reduction in microcirculatory resistance
due to dilation of small blood vessels and therefore an
increase in intramyocardial blood volume. The sub-
sequent BCW generated by compression of the
intramyocardial blood vessels has a proportionately
greater increase with adenosine compared with the
other waves.
IMPACT ON POTENTIAL TREATMENT STRATEGIES.
WIA might explain the improvement in myocardial
perfusion seen with beta-blockers and calcium chan-
nel blockers (28). Both increase diastolic duration and
reduce myocardial contractility, theoretically leading
to a reduction in BCW. Improvements in myocardial
perfusion (29,30) and CFR (31) after septal reduction
therapy have been assumed to result from reduction
in intracavity pressures and reduced microvascular
compression. Beneﬁt might also result from elimina-
tion of the FEWa.
Treatment strategies that reduce decelerating
waves, either of proximal or distal origin, will
improve the efﬁciency of coronary ﬂow and should
therefore improve myocardial perfusion. Because
perfusion abnormalities are common in HCM, treat-
ments that prolong diastolic duration may be
beneﬁcial in all patients, not just those who are
symptomatic.
STUDY LIMITATIONS. Recruited patients had a clin-
ical indication for coronary angiography. Patients
with HCM were therefore symptomatic, and their
results may not be generalizable to the asymptom-
atic population. However, the patients recruited
were representative of the subset of HCM that poses
the greatest management challenge for clinicians.
Control subjects typically had risk factors for coro-
nary disease, including hypertension and diabetes,
and had low-to-normal values of MPR; therefore,
a degree of mild microvascular disease may have
been present. If completely healthy control subjects
had been recruited, there may have been even
greater differences compared with those with HCM.
Use of beta-blockers and angiotensin-converting
enzyme inhibitors differed between the 2 pop-
ulations, and we did not adjust for this factor in the
analysis.
The mean age of patients with HCM was 54 years
(range 22 to 74 years). Accordingly, our ﬁndings
cannot be generalized to the pediatric or adolescent
population. However, the results seemed similar in
the 6 patients <40 years of age compared with the
rest of the sample.
CENTRAL ILLUSTRATION Wave Intensity Analysis and Magnetic Resonance in HCM
Raphael, C.E. et al. J Am Coll Cardiol. 2016;68(15):1651–60.
There are 3 main mechanisms that result in abnormal myocardial perfusion in hypertrophic cardiomyopathy (HCM) involving waves causing coronary ﬂow acceleration
(black arrows) and those leading to deceleration (white arrows; each arrow is in the direction of the underlying wave, rather than the direction of coronary ﬂow).
Compression and deformation of the microcirculation result in a large backward compression wave (BCW) during ventricular systole. In patients with severe left
ventricular outﬂow tract (LVOT) obstruction, an additional forward deceleration wave decreases the proximal driving pressure during mid-to-late systole, further
diminishing coronary forward ﬂow. During diastole, impaired ventricular relaxation results in a proportionately smaller backward expansion wave (BEW). FCW ¼ forward
compression wave; FEWa ¼ additional forward expansion wave.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Myocardial
perfusion abnormalities in patients with HCM are caused by
compression of the microcirculation, LVOT obstruction, and
impaired ventricular relaxation rather than a supply/demand
mismatch or microcirculatory remodeling.
TRANSLATIONAL OUTLOOK: Future research should assess
whether treatment of perfusion abnormalities can improve
clinical outcomes in patients with HCM.
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1659Separated WIA requires knowledge of the local
wave speed, and the use of the sum-of-squares esti-
mate for wave speed introduces some uncertainty
into the calculations. However, small errors in the
wave speed have been shown to have little effect
on the pattern of separated wave intensity (32);
moreover, the net WIA, which does not depend
on estimation of wave speed, produced similar
results.
CONCLUSIONS
WIA in patients with HCM demonstrated that coro-
nary ﬂow abnormalities occur due to opposing prox-
imal and distal effects resulting from compression
and deformation of the intramural blood vessels and
impaired ventricular relaxation. LVOT obstruction
might generate an additional deceleration wave.
These abnormalities result in impaired myocardial
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